Abstract
To estimate the prevalence of TP53 mutations in familial breast cancer, constant denaturant gel electrophoresis (CDGE) was used to screen exons 5-8 of the TP53 gene for germline mutations. Genomic DNA from 128 breast cancer patients belonging to 109 families with familial cancer were screened. No germline mutations were found in any of the patients. We also studied TP53 mutations in tumour DNA from 51 of the same individuals and found mutations in 14%. This is similar to what has been reported in sporadic breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zelada-Hedman, M., Børresen-Dale, AL., Claro, A. et al. Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families. Br J Cancer 75, 1201–1204 (1997). https://doi.org/10.1038/bjc.1997.205
Issue Date:
DOI: https://doi.org/10.1038/bjc.1997.205
This article is cited by
-
New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer
Familial Cancer (2021)
-
The R72P P53 mutation is associated with familial breast cancer in Jewish women
British Journal of Cancer (2005)
-
Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India
Breast Cancer Research and Treatment (2004)